Annovis Bio, Inc. · NYSE:ANVS
Annovis Bio — Investor Presentation (June 2020)
24 slides from Annovis Bio's investor presentation, Jun 9, 2020
Slide 1: Attacks Alzheimer's Disease and Neurodegeneration by Improving Axonal Transport
Attacks Alzheimer’s Disease and Neurodegeneration by Improving the Information Highway of the Nerve Cell Axonal Transport June 2020 Symbol: ANVS (NYSE American)
Slide 2: Forward-Looking Statements
FORWARD - LOOKING STATEMENTS Statements in this presentation contain “forward - looking statements” that are subject to substantial risks and uncertainties. Forward - looking statements contained in this presentation may be identified by the use of words such as “anticipate,” “expect,” “believe,” “w
Slide 3: Highlights
3 ▪ Annovis is developing drugs for Alzheimer's (AD) and Parkinson's disease (PD), including the orphan indication Alzheimer's in Down Syndrome (AD - DS) ▪ Lead compound, ANVS401, is the only drug to improve axonal transport, the information highway of the nerve cell, by attacking multiple neurotoxi
Slide 4: The State of Alzheimer's Disease
THE STATE OF ALZHEIMER’S DISEASE ▪ Alzheimer's is the most common cause of dementia, a general term for memory loss and other cognitive abilities serious enough to interfere with daily life. Alzheimer's disease accounts for 60 to 80 percent of dementia cases. ▪ 1 in 6 females and 1 in 11 males have
Slide 5: Alzheimer's Drug Trial Failures
ALZHEIMER’S DRUG TRIAL FAILURES Have researchers been on the wrong track with amyloid? 5 The idea that sticky brain plaques cause Alzheimer’s disease began as an interesting hypothesis and eventually became drug industry dogma. Now, after a string of clinical trial failures, that hypothesis looks le
Slide 6: Annovis' Drug Treats AD and PD
Chronic and acute brain insults lead to high levels of neurotoxic proteins, to inflammation and neurodegeneration Attacking one neurotoxic protein results in minimal effect ANVS401 is the only drug to attack multiple neurotoxic proteins simultaneously Amyloid β AD / PD - A β Targeting Compounds ANNO
Slide 7: Pipeline
DISEASE NEUROTOXIC PROTEIN TARGET PRE - CLINICAL IND PHASE 1 PHASE 2 AD (AD - DS) PD TBI Advanced AD APP, tau, aSYN aSYN , APP Tau, APP, aSYN BChEl PIPELINE Oral drug for chronic indications injectable drug for acute traumatic events oral drug for advanced AD and dementia 7
Slide 8: Corporate Patent Estate
8 CORPORATE PATENT ESTATE Patent/Application Subject Matter Status US Expiry US Provisional ANVS401 to treat viral and bacterial infections of the brain, including Covid19 Pending 2041 PCT ANVS401 and 405 - Method of use of MOA for prevention and treatment of diseases Pending 2038 PCT ANVS405 - Acut
Slide 9: How Nerve Cells Work
NEUROTRANSITTERS THAT TRAVEL ACCROSS THE AXON Adrenaline Noradrenaline Dopamine HOW NERVE CELLS WORK In healthy nerve cells little packages containing neurotransmitters or nerve growth factors travel unimpaired from the cell body through the axon to the synapse. SOMA & CELL BODY DENDRITES Serotonin
Slide 10: Neurotoxic Proteins Impair Axonal Transport and Cause a Toxic Cascade
NEUROTOXIC PROTEINS IMPAIR AXONAL TRANSPORT AND CAUSE A TOXIC CASCADE ANVS401 IMPROVES AXONAL TRANSPORT AND IMPEDES THE TOXIC CASCADE IMPAIRED AXONAL TRANSPORT SLOWER SYNAPTIC TRANSMISSION INFLAMMATION DEATH OF NERVE CELLS LOSS OF COGNITIVE AND MOTOR FUNCTION IMPROVED AXONAL TRANSPORT INCREASED SYNA
Slide 11: Results in Humans
11 RESULTS IN HUMANS ANVS401 Lowers Neurotoxic Proteins in Spinal Fluid of MCI Patients ▪ In this proof of concept study, ANVS401 lowers the levels of APP/Aβ, tau/p - tau and αSYN back to the levels seen in healthy volunteers ▪ It lowers the levels of the three neurotoxic proteins causing AD and PD
Slide 12: Neurodegeneration Is an Axonal Transport Disease
NEURODEGENERATION IS AN AXONAL TRANSPORT DISEASE Axonal transport is responsible for: Normal Transport The Normal Flow and Speed of vesicles carrying BDNF across the axon. ▪ Neurotransmitters GABA (anxiety), ACh (cognition), dopamine (movement), serotonin (mood) ▪ Neurotrophic factors NGF, BDNF ▪ Al
Slide 13: ANVS401 Lowers Inflammatory Markers
13 ANVS401 LOWERS INFLAMMATORY MARKERS Maccecchini et al: JNNP 2012; 83: 894 - 902 CSF Inflammatory Markers Significantly Decrease After 10 Days of Oral ANVS401 in MCI Patients Inflammatory Protein CSF % of Baseline p - Value Complement C3 - 86.9% 0.0007 MCP - 1 - 87.5% 0.0007 YKL40 - 72.7% 0.0113 s
Slide 14: Results in Animals
14 RESULTS IN ANIMALS 19 animal studies showed that ANVS401 and ANVS405 improved the affected function x ANVS401 and ANVS405 increased memory and learning in three animal models: ▪ AD tg mice ▪ DS trisomic mice ▪ TBI rats x Improved gut motility in PD tg mice x Stabilized brain chemistry in FTD tau
Slide 15: Two Phase 2 Clinical Trials in AD and PD
15 TWO PHASE 2 CLINICAL TRIALS IN AD AND PD TRIALS 1) AD with 24 patients for one month - ongoing (14 patients treated) 2) PD and AD with 68 patients for one month - to start in June ENDPOINTS Target Engagement Decrease in neurotoxic protein levels Pathway Engagement Increase in neurotransmitters an
Slide 16: Clinical – Overview
16 CLINICAL – OVERVIEW CRO Parexel Therapeutic Area Early Alzheimer's and Parkinson's Diseases Phase 2 Design Double - Blind, Placebo - Controlled, 2 - Cohort Biomarker Study Country United States Sites Up to 15 Sites Patients 68 Part 1 - Comparison of 14 AD vs 14 PD Patients Part 2 - Dose Response
Slide 17: Clinical – Site Update
17 CLINICAL – SITE UPDATE Backup Approved for Selection Contacted In Progress 15 Sites With Additional Back - Up Sites
Slide 18: Clinical – Timelines
CLINICAL - TIMELINES The two - part clinical study is being set up at 15 sites in the US and will begin in June 2020. The AD/PD comparison is projected to be concluded by the end of the year and preliminary data will be available in early 1Q2021 The dose response is projected to be completed by mid
Slide 19: Market Projections
1% 2% 4% 8% 16% 47% 60-65 65-70 70-75 75-80 80-85 85+ 19 MARKET PROJECTIONS Source: Alzheimer‘s Association 2014; Incidence of AD in Relation to Age Increase in Incidence with Aging of Population Annual sales potential for US and worldwide are over $100 billion dollars
Slide 20: Chief Executives and Chief Advisors
CHIEF EXECUTIVES AND CHIEF ADVISORS Jeffrey Cummings, MD, Chief Medical Advisor Dr . Cummings completed Neurology residency and a Fellowship in Behavioral Neurology at Boston University, Boston, Massachusetts . US training was followed by a Research Fellowship in Neuropathology and Neuropsychiatry a
Slide 21: Scientific Advisory Board
SCIENTIFIC ADVISORY BOARD 21 Sidney Strickland, PhD, Chairman Vice President and Dean for Educational Affairs and Research Professor, Patricia and John Rosenwald Laboratory of Neurobiology and Genetics at Rockefeller University. Dr. Strickland’s laboratory investigates how dysfunction of the circula
Slide 22: Board of Directors
22 Michael B . Hoffman Chairman Mr . Hoffman is the Founder and Managing Partner of Stone Capital Partners, a private equity firm focused on power and renewable energy . He was Partner of Riverstone, senior managing director at the Blackstone Group and managing director at Smith Barney, Harris Upham
Slide 23: Investment Summary
INVESTMENT SUMMARY A novel approach to treat neurodegeneration is desperately needed ▪ The markets for AD and PD drugs are in the multibillions of dollars and growing ▪ Annovis has a novel solution to stop the course of AD and PD ▪ ANVS401 improves axonal transport and homeostasis in the brain and r
Slide 24: Contact Us
Improves THE FLOW of Axonal Transport in Alzheimer’s Disease and Neurodegeneration CONTACT US 1055 Westlakes Drive Suite 300 Berwyn, PA 19312 +1 (610) 727 3913 info@annovisbio.com www.annovisbio.com Symbol: ANVS (NYSE American)